Company: TXG
Filing Date: 2025-11-07
Form Type: 10-Q
Source: 0001628280-25-050332
Chunk: 18

Company: 10x Genomics, Inc.
Filing Date: 2025-11-07
Form: 10-Q
Item: Part I, Item 1
Chunk 18
---
2,971 202616,612 202716,799 202816,382 202914,788 Thereafter39,314 Total lease payments$106,866 Less: imputed interest(19,881)Present value of operating lease liabilities$86,985 Operating lease liabilities, current$10,543 Operating lease liabilities, noncurrent76,442 Total operating lease liabilities$86,985 The following table summarizes additional information related to operating leases as of September 30, 2025:September 30,2025December 31,2024Weighted-average remaining lease term6.9 years6.8 yearsWeighted-average discount rate5.9 %5.8 %

15

Table of Contents10x Genomics, Inc.Notes to Unaudited Condensed Consolidated Financial Statements

LitigationThe Company is regularly subject to lawsuits, claims, arbitration proceedings, administrative actions and other legal and regulatory proceedings involving intellectual property disputes, commercial disputes, competition and other matters, and the Company may become subject to additional types of lawsuits, claims, arbitration proceedings, administrative actions, government investigations and legal and regulatory proceedings in the future. As of September 30, 2025, the Company has concluded that a loss is not probable and a contingent liability has not been recorded.ParseIn August 2022, the Company filed suit against Parse Biosciences, Inc. (“Parse”) in the U.S. District Court for the District of Delaware alleging that Parse’s Evercode Whole Transcriptomics products and ATAC-seq products infringe U.S. Patent Nos. 10,155,981 (the “981 patent”), 10,697,013 (the “013 patent”), 10,240,197 (the “197 patent”), 10,150,995 (the “995 patent”), 10,619,207 (the “207 patent”) and 10,738,357 (the “357 patent”). In February 2025, the Court entered a consent judgment and permanent injunction against Parse with respect to the 995, 207 and 357 patents relating to ATAC-seq.  Parse filed petitions for Inter Partes Review (“IPR”) of the 981, 197 and 013 patents which were found unpatentable by the Patent Trial and Appeals Board in February 2025. The Company strongly disagrees with those decisions and has appealed. The Court has stayed the litigation pending the outcome of the appeals.In August 2025, the Company acquired